TriangleNCT02668653 · CITED IN SOURCE DOCUMENTS
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2024-08-06
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML). Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State
Pharmacokinetic Parameter Steady State, Maximum Plasma Concentration (Css,Max)
Pharmacokinetic Parameter Time to Maximum Plasma Concentration Steady State (Tmax,ss)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Must be competent and able to comprehend, sign, and date an Ethics Committee (EC) or Institutional Review Board approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests; 2. Is ≥18 years or the minimum legal adult age (whichever is greater) and ≤75 years (at Screening); 3. Newly diagnosed, morphologically documented primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, based on the World Health Organization (WHO) 2008 classification (at Screening); 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (at the time the participant signs their first ICF); 5. Presence of FLT3-ITD activating mutation in bone marrow (allelic ratio of ≥3% FLT3-ITD/total FLT3); 6. Participant is receiving standard "7+3" induction chemotherapy regimen as specified in the protocol; 7. Adequate renal function defined as: a. Creatinine clearance \>50 mL/min, as calculated with the modified Cockcroft Gault equation 8. Adequate hepatic function defined as: 1. Total serum bilirubin (TBL) ≤1.5 × upper limit of normal (ULN) unless the participant has documented Gilbert's syndrome or the increase is related to increased unconjugated (indirect) bilirubin due to hemolysis; 2. Serum alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × ULN; 9. Serum electrolytes within normal limits: potassium, calcium (total, or corrected for serum albumin in case of hypoalbuminemia or ionized calcium) and magnesium. If outside of normal limits, participant will be eligible when electrolytes are corrected; 10. If a woman of childbearing potential, must have a negative serum pregnancy test upon entry into this study and must be willing to use highly effective birth control upon enrollment, during the treatment period and for 6 months following the last dose of investigational drug or cytarabine, whichever is later. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months); 11. If male, must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for 6 months following the last dose of investigational drug or cytarabine, whichever is later. Exclusion Criteria: 1. Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy). 2. Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms; 3. Prior treatment for AML, except for the following allowances: * Leukapheresis; * Treatment for hyperleukocytosis with hydroxyurea; * Cranial radiotherapy for central nervous system (CNS) leukostasis; * Prophylactic intrathecal chemotherapy; * Growth factor/cytokine support; 4. Prior treatment with quizartinib or other FLT3-ITD inhibitors; 5. Prior treatment with any investigational drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures; 6. History of known CNS leukemia, including cerebrospinal fluid positive for AML blasts; lumbar puncture is recommended for participants with symptoms of CNS leukemia to rule out extramedullary CNS involvement; 7. History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for at least 2 years; 8. Uncontrolled or significant cardiovascular disease, including any of the following: * Bradycardia of less than 50 beats per minute, unless the participant has a pacemaker; * Fridericia's Heart Rate Correction Formula (QTcF) interval \>450 msec; * Diagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome); * Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg; * History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes); * History of second (Mobitz II) or third degree heart block (participants with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker); * History of uncontrolled angina pectoris or myocardial infarction within 6 months prior to Screening; * History of New York Heart Association Class 3 or 4 heart failure; * Known history of left ventricular ejection fraction (LVEF) ≤45% or less than the institutional lower limit of normal; * Complete left bundle branch block; 9. Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy; 10. Known active clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C); 11. Known history of human immunodeficiency virus (HIV). Participants should be tested for HIV prior to Randomization if required by local regulations or EC; 12. History of hypersensitivity to any excipients in the quizartinib/placebo tablets; 13. Females who are pregnant or breastfeeding; 14. Otherwise considered inappropriate for the study by the Investigator.
- healthy Volunteers
- false
- maximum Age
- 75 Years
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant Continuation: up to 36 cycles with the experimental drug quizartinib
- intervention Names
- Drug: Chemotherapy
- Drug: Quizartinib
- label
- Chemotherapy plus quizartinib
- type
- EXPERIMENTAL
- description
- Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant Continuation: up to 36 cycles with placebo
- intervention Names
- Drug: Chemotherapy
- Drug: Placebo
- label
- Chemotherapy plus placebo
- type
- ACTIVE_COMPARATOR
- interventions
- arm Group Labels
- Chemotherapy plus placebo
- Chemotherapy plus quizartinib
- name
- Chemotherapy
- other Names
- Cytarabine
- Daunorubicin
- Idarubicin
- type
- DRUG
- arm Group Labels
- Chemotherapy plus quizartinib
- name
- Quizartinib
- other Names
- Test Product
- type
- DRUG
- arm Group Labels
- Chemotherapy plus placebo
- name
- Placebo
- other Names
- Placebo Control
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- TRIPLE
- who Masked
- PARTICIPANT
- INVESTIGATOR
- OUTCOMES_ASSESSOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 539
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Overall survival is defined as the time from randomization until death from any cause.
- measure
- Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
- time Frame
- Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment
- secondary Outcomes
- description
- Event-free survival (EFS) is the time from randomization to the earliest date of either refractory disease (or treatment failure \[TF\]), relapse, or death from any cause. Refractory disease is defined as complete remission never achieved during Induction (CR: \>1000 neutrophils, \>100,000 platelets, \<5% blasts, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]). For refractory disease, EFS event date is Day 1 (randomization). Relapse after CR is defined as ≥5% blasts, leukemic blasts, extramedullary leukemia, and presence of rods. This analysis is based on a response assessment with TF defined as not achieving response of CR, using a 42- day window from the start of the last cycle in Induction for CR evaluation.
- measure
- Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
- time Frame
- Date of randomization to the date of refractory disease, relapse, or death, up to approximately 3 years after enrollment
- description
- Complete remission (CR) rate is defined as the percentage of participants achieving CR, defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], after induction
- measure
- Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
- time Frame
- Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)
- description
- Composite complete remission (CRc) rate is defined as the percentage of participants whose best response is complete remission (CR), defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi) at the end of first Induction cycle.
- measure
- Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
- time Frame
- Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)
- description
- A treatment-emergent adverse event (TEAE) is defined as an adverse event that occur, having been absent before first dose of quizartinib or placebo, or have worsened in severity after initiating quizartinib or placebo. Adverse events collected more than 30 days after the last dose of quizartinib/placebo will not be considered TEAEs unless they are considered drug-related.
- measure
- Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
- time Frame
- Date of first dose up to 30 days after last dose, up to 36 cycles following continuation (approximately 6 years 11 months, each cycle is 28 days)
- description
- Complete remission (CR) is defined as participants achieving CR defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]. Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.
- measure
- Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
- time Frame
- Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)
- description
- Composite complete remission (CRc) is defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi). Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.
- measure
- Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
- time Frame
- Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)
- description
- AUCss was assessed by population Pharmacokinetic (PK) analysis during Cycle 1 of each phase.
- measure
- Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State
- time Frame
- Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
- description
- Css,max was assessed by population PK analysis during Cycle 1 of each phase.
- measure
- Pharmacokinetic Parameter Steady State, Maximum Plasma Concentration (Css,Max)
- time Frame
- Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
- description
- Tmax,ss was assessed by population PK analysis during Cycle 1 of each phase.
- measure
- Pharmacokinetic Parameter Time to Maximum Plasma Concentration Steady State (Tmax,ss)
- time Frame
- Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
Full study description
- brief Summary
- Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML). Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.
- detailed Description
- This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of this study is to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as continuation therapy for up to 36 cycles) on overall survival in subjects with FLT3-internal tandem duplication (ITD) positive AML.
Source references
- references
- citation
- Levis MJ, Erba HP, Montesinos P, Patkowska E, Cortes J, Perl AE, Dombret H, Amadori S, Wang J, Schlenk RF, Liu L, Mostafa Kamel Y, Imadalou K, Laadem A, Burns K, Sekeres MA. Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. Blood Adv. 2026 Jun 23;10(12):4144-4159. doi: 10.1182/bloodadvances.2025017738.
- pmid
- 41949390
- type
- DERIVED
- citation
- Oliva EN, Cottone F, Unni S, Correges A, Hansen JB, Marston XL, Cortes J, Sekeres MA. Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2026 Mar;13(3):e169-e180. doi: 10.1016/S2352-3026(25)00361-8.
- pmid
- 41791832
- type
- DERIVED
- citation
- Levis MJ, Erba HP, Montesinos P, Kim HJ, Vrhovac R, Patkowska E, Zak P, Wang PN, Connolly Rohrbach JE, Chang KCN, Liu L, Mostafa Kamel Y, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Perl AE. FLT3-ITD measurable residual disease from the QuANTUM-First trial. Blood Adv. 2026 Feb 10;10(3):917-928. doi: 10.1182/bloodadvances.2025016444.
- pmid
- 41052406
- type
- DERIVED
- citation
- Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, Zak P, Wang PN, Hanyok J, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP. Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial. Haematologica. 2025 Sep 1;110(9):2024-2039. doi: 10.3324/haematol.2024.286623. Epub 2025 Mar 13.
- pmid
- 40079105
- type
- DERIVED
- citation
- Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Zak P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25.
- pmid
- 37116523
- type
- DERIVED
- citation
- Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Kramer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.
- pmid
- 29859851
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-84cbeeeebf20bad1bb27
- requested nct id
- NCT02668653
- primary nct id
- NCT02668653
- source kind
- fda_spl_label
- source record id
- ee05ebbe-cace-4b2f-bb89-c26687c1eeaf
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 13142a4ebce7a90c4ba4d65fa9a12b7e86e0f654afe3f755ed0a019a0b8045c5
- payload
- application numbers
- NDA216993
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-84cbeeeebf20bad1bb27
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02668653
- occurrences
- context exact
- 14 CLINICAL STUDIES The efficacy of VANFLYTA in combination with chemotherapy was evaluated in QuANTUM-First (NCT02668653), a randomized, double-blind, placebo-controlled study of 539 patients with newly diagnosed FLT3-ITD positive AML. FLT3-ITD status was determined prospectively
- end
- 121
- exact text
- NCT02668653
- start
- 110
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/92/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- ee05ebbe-cace-4b2f-bb89-c26687c1eeaf
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- dd0e842398d230610bd581bfba7c9a1eba4f29f7c16d3806e76885442697e36f
- spl effective time
- 20260416
- spl set id
- 29cdbcfe-497d-4e78-bb7b-2d4acafe8e86
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e1430202b044f70dbc2a
- requested nct id
- NCT02668653
- primary nct id
- NCT02668653
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 34fd1fb9f30a06b79415d02c9e1ed422ade2f4bc02b2c78ec5acbb31f3ab7575
- payload sha256
- 85aea08bf24512899940e0acecf7ab0da66708835336deb4a02c8662e3c86537
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e1430202b044f70dbc2a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02668653
- occurrences
- context exact
- 1">Evidence (quizartinib):</p> <div class="pdq-content-list"><ol id="_810"><li>A multicenter, randomized, phase III trial (<a href="/clinicaltrials/NCT02668653">NCT02668653</a>) included patients with <em class="gene-name">FLT3</em>-ITD–altered AML. Patients received either the selective ITD-specific FLT3 inhibi
- end
- 155433
- exact text
- NCT02668653
- start
- 155422
- context exact
- quizartinib):</p> <div class="pdq-content-list"><ol id="_810"><li>A multicenter, randomized, phase III trial (<a href="/clinicaltrials/NCT02668653">NCT02668653</a>) included patients with <em class="gene-name">FLT3</em>-ITD–altered AML. Patients received either the selective ITD-specific FLT3 inhibitor, quizarti
- end
- 155446
- exact text
- NCT02668653
- start
- 155435
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/18d2b12fbb5f0650e6.html
- source file sha256
- 34fd1fb9f30a06b79415d02c9e1ed422ade2f4bc02b2c78ec5acbb31f3ab7575
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:53.074610+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 454d4af27284fdd87ef57958565fbfaa1f8cabea4d6a7515759997a5fb0fc65e
- source title
- Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: March 14, 2025
- datetime
- 2025-03-14T12:00:00Z
- display
- March 14, 2025
Preserved source evidence · Not medical advice